Wuhan Hiteck Biological Pharma Co Ltd (300683) — Capital Reinvestment Ratio

Latest as of September 2024: 1.14x

Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Capital Reinvestment Ratio of 1.14x as of September 2024, meaning it reinvests 1% of its operating cash flow (CN¥4.86 Million) in capital expenditures (CN¥5.52 Million). See Wuhan Hiteck Biological Pharma Co Ltd (300683) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

1.14x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥4.86 Million
CNY

Capital Expenditures

CN¥5.52 Million
CNY

Data as of

Sep 2024
Most recent filing

Wuhan Hiteck Biological Pharma Co Ltd Capital Reinvestment Ratio (2013–2024)

This chart tracks Wuhan Hiteck Biological Pharma Co Ltd's Capital Reinvestment Ratio across 11 annual periods.

Annual Capital Reinvestment Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)

Year-by-year Capital Reinvestment Ratio for Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024. For live market cap and broader valuation context, see 300683 market cap.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 1.90x CN¥22.69 Million CN¥43.08 Million ▼ -94.0%
2023 31.51x CN¥5.31 Million CN¥167.44 Million ▲ +860.5%
2022 3.28x CN¥53.03 Million CN¥173.97 Million ▼ -84.0%
2021 20.44x CN¥12.09 Million CN¥247.11 Million ▲ +1009.2%
2019 1.84x CN¥63.03 Million CN¥116.15 Million ▲ +249.9%
2018 0.53x CN¥73.42 Million CN¥38.67 Million ▲ +96.6%
2017 0.27x CN¥83.08 Million CN¥22.25 Million ▲ +74.8%
2016 0.15x CN¥143.86 Million CN¥22.05 Million ▲ +79.9%
2015 0.09x CN¥159.89 Million CN¥13.62 Million ▼ -26.3%
2014 0.12x CN¥135.40 Million CN¥15.64 Million ▼ -43.5%
2013 0.20x CN¥76.82 Million CN¥15.71 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow